This special issue provides a platform for recent advances in radiation therapy, bringing together contributions from materials science, molecular imaging, and oncology.
Explore it now: buff.ly/cSnDhaa
Explore it now: buff.ly/cSnDhaa
December 31, 2025 at 6:04 PM
This special issue provides a platform for recent advances in radiation therapy, bringing together contributions from materials science, molecular imaging, and oncology.
Explore it now: buff.ly/cSnDhaa
Explore it now: buff.ly/cSnDhaa
The latest issue of ACS Applied Materials & Interfaces (@ACS_AMI) is live! On the #cover of the special issue “#Innovations in #Radiotherapeutic #Materials for #Personalized #Oncology” providing a #platform for these advances in the evolving landscape of #cancer #treatment
December 17, 2025 at 3:58 PM
The latest issue of ACS Applied Materials & Interfaces (@ACS_AMI) is live! On the #cover of the special issue “#Innovations in #Radiotherapeutic #Materials for #Personalized #Oncology” providing a #platform for these advances in the evolving landscape of #cancer #treatment
Study Shows Promise of Emerging Radiotherapeutic Agent for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
www.diagnosticimaging.com/view/study-e...
#radiology #RadRes #EANM25 #NuclearMedicine
www.diagnosticimaging.com/view/study-e...
#radiology #RadRes #EANM25 #NuclearMedicine
October 22, 2025 at 8:37 PM
Study Shows Promise of Emerging Radiotherapeutic Agent for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
www.diagnosticimaging.com/view/study-e...
#radiology #RadRes #EANM25 #NuclearMedicine
www.diagnosticimaging.com/view/study-e...
#radiology #RadRes #EANM25 #NuclearMedicine
Humphrey Fonge doesn't just create cancer therapeutics - he wants to ensure they reach the patients who need them.
Fonge and his team at Université Laval have developed a radiotherapeutic which targets Nectin-4, a protein in many cancers.
Watch the full interview: www.youtube.com/watch?v=nTdJ...
Fonge and his team at Université Laval have developed a radiotherapeutic which targets Nectin-4, a protein in many cancers.
Watch the full interview: www.youtube.com/watch?v=nTdJ...
In Their Own Words: Humphrey Fonge
YouTube video by BioCanRx - Canada's Immunotherapy Network
www.youtube.com
September 3, 2025 at 4:01 PM
Humphrey Fonge doesn't just create cancer therapeutics - he wants to ensure they reach the patients who need them.
Fonge and his team at Université Laval have developed a radiotherapeutic which targets Nectin-4, a protein in many cancers.
Watch the full interview: www.youtube.com/watch?v=nTdJ...
Fonge and his team at Université Laval have developed a radiotherapeutic which targets Nectin-4, a protein in many cancers.
Watch the full interview: www.youtube.com/watch?v=nTdJ...
MP is looking for exemption from customs duties for imported immunotherapy, radiotherapeutic equipment for cancer treatment
A rural deputy Bengalur and CN CN Manjunath was looking for an exception of customs duties for all imported immunotherapeutic drugs and radiotherapeutic equipment, which are…
A rural deputy Bengalur and CN CN Manjunath was looking for an exception of customs duties for all imported immunotherapeutic drugs and radiotherapeutic equipment, which are…
MP is looking for exemption from customs duties for imported immunotherapy, radiotherapeutic equipment for cancer treatment
A rural deputy Bengalur and CN CN Manjunath was looking for an exception of customs duties for all imported immunotherapeutic drugs and radiotherapeutic equipment, which are now an integral part of advanced cancer treatment. Dr. Manjunath, who met the Minister of Finance Nirmala Seetharaman on Wednesday, has submitted an exemption application because most immunotherapeutic drugs and radiotherapeutic equipment are currently imported.
techwordnews.com
August 22, 2025 at 4:14 AM
MP is looking for exemption from customs duties for imported immunotherapy, radiotherapeutic equipment for cancer treatment
A rural deputy Bengalur and CN CN Manjunath was looking for an exception of customs duties for all imported immunotherapeutic drugs and radiotherapeutic equipment, which are…
A rural deputy Bengalur and CN CN Manjunath was looking for an exception of customs duties for all imported immunotherapeutic drugs and radiotherapeutic equipment, which are…
This study, using retrospective data on 2,824 #meningiomas, highlights the potential for #MolecularProfiling to refine #surgical and #radiotherapy decision-making.
Read more: go.nature.com/3GygVIj
Read more: go.nature.com/3GygVIj
July 16, 2025 at 10:05 AM
This study, using retrospective data on 2,824 #meningiomas, highlights the potential for #MolecularProfiling to refine #surgical and #radiotherapy decision-making.
Read more: go.nature.com/3GygVIj
Read more: go.nature.com/3GygVIj
$PSTV +105% [FDA cleared IND for REYOBIQ™ (Re186 Obisbemeda) for ReSPECT-PBC trial, a novel radiotherapeutic for pediatric HGG & ependymoma to improve outcomes.] ir.plustherapeutics.com/news-release...
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer | Plus Therapeutics, Inc.
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE...
ir.plustherapeutics.com
June 25, 2025 at 12:31 PM
$PSTV +105% [FDA cleared IND for REYOBIQ™ (Re186 Obisbemeda) for ReSPECT-PBC trial, a novel radiotherapeutic for pediatric HGG & ependymoma to improve outcomes.] ir.plustherapeutics.com/news-release...
Radiopharm Theranostics signs Terbium supply agreement with Cyclotek to support its RAD402 Ph1 clinical trial in prostate cancer. RAD 402 is an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic.
$RADX
finance.yahoo.com/news/radioph...
$RADX
finance.yahoo.com/news/radioph...
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY a...
finance.yahoo.com
June 24, 2025 at 2:04 PM
Radiopharm Theranostics signs Terbium supply agreement with Cyclotek to support its RAD402 Ph1 clinical trial in prostate cancer. RAD 402 is an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic.
$RADX
finance.yahoo.com/news/radioph...
$RADX
finance.yahoo.com/news/radioph...
Nanotech Targets Glioblastoma Resection Margins Locoregionally
The relentless challenge posed by glioblastoma multiforme (GBM), the most aggressive and lethal primary brain tumor, continues to galvanize oncological research worldwide. Despite advances in surgical, radiotherapeutic, and…
The relentless challenge posed by glioblastoma multiforme (GBM), the most aggressive and lethal primary brain tumor, continues to galvanize oncological research worldwide. Despite advances in surgical, radiotherapeutic, and…
Nanotech Targets Glioblastoma Resection Margins Locoregionally
The relentless challenge posed by glioblastoma multiforme (GBM), the most aggressive and lethal primary brain tumor, continues to galvanize oncological research worldwide. Despite advances in surgical, radiotherapeutic, and chemotherapeutic strategies, patient prognosis remains dismal, with median survival rarely exceeding 15 months post-diagnosis. Central to this grim outlook is the infiltrative nature of glioblastoma cells, which invade beyond the conspicuous tumor mass into surrounding brain tissue, rendering complete eradication through resection alone impossible.
scienmag.com
May 31, 2025 at 10:48 AM
Nanotech Targets Glioblastoma Resection Margins Locoregionally
The relentless challenge posed by glioblastoma multiforme (GBM), the most aggressive and lethal primary brain tumor, continues to galvanize oncological research worldwide. Despite advances in surgical, radiotherapeutic, and…
The relentless challenge posed by glioblastoma multiforme (GBM), the most aggressive and lethal primary brain tumor, continues to galvanize oncological research worldwide. Despite advances in surgical, radiotherapeutic, and…
#CSBR Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
https://www.stocktitan.net/news/CSBR/champions-oncology-obtains-radioactive-materials-license-to-advance-jqvqgr1fspd0.html
https://www.stocktitan.net/news/CSBR/champions-oncology-obtains-radioactive-materials-license-to-advance-jqvqgr1fspd0.html
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
Champions Oncology (NASDAQ:CSBR) has secured a radioactive materials license, enabling in-house preclinical studies with various radionuclides. This development enhances the company's capabilities in developing and evaluating targeted radiotherapeutics.The license allows Champions to combine radionuclide-based therapeutic testing with their existing patient derived xenograft (PDX) models platform under one roof. The integrated program will support drug developers in various modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.CEO Ronnie Morris emphasized that this license represents a significant milestone in supporting biopharmaceutical partners developing next-generation radiotherapeutics, positioning the company to advance radiopharmaceutical development with enhanced translational precision.
www.stocktitan.net
April 28, 2025 at 1:46 PM
#CSBR Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
https://www.stocktitan.net/news/CSBR/champions-oncology-obtains-radioactive-materials-license-to-advance-jqvqgr1fspd0.html
https://www.stocktitan.net/news/CSBR/champions-oncology-obtains-radioactive-materials-license-to-advance-jqvqgr1fspd0.html
Microbial Photosynthetic Oxygenation and Radiotherapeutic Sensitization Enables Pyroptosis Induction for Combinatorial Cancer Therapy advanced.onlinelibrary.wiley.com/doi/10.1002/...
Microbial Photosynthetic Oxygenation and Radiotherapeutic Sensitization Enables Pyroptosis Induction for Combinatorial Cancer Therapy
This study reports the preparation of lanthanum oxide nanoparticles (La2O3 NPs) via a solid-phase synthesis method, combined with cyanobacteria (Cyan) to effectively alleviate hypoxia. These componen....
advanced.onlinelibrary.wiley.com
April 28, 2025 at 10:27 AM
Microbial Photosynthetic Oxygenation and Radiotherapeutic Sensitization Enables Pyroptosis Induction for Combinatorial Cancer Therapy advanced.onlinelibrary.wiley.com/doi/10.1002/...
the production of radiotherapeutic $^{177}$Lu according to a 10 mA, 18 MeV $D^+$ compact linear accelerator. The design comprises a single radio-frequency quadrupole accelerator (RFQ) and seven drift tube linacs (DTLs) that achieve a beam efficiency [2/5 of https://arxiv.org/abs/2503.05608v1]
March 10, 2025 at 6:16 AM
the production of radiotherapeutic $^{177}$Lu according to a 10 mA, 18 MeV $D^+$ compact linear accelerator. The design comprises a single radio-frequency quadrupole accelerator (RFQ) and seven drift tube linacs (DTLs) that achieve a beam efficiency [2/5 of https://arxiv.org/abs/2503.05608v1]
A CDE-based data structure for radiotherapeutic decision-making in breast cancer https://www.medrxiv.org/content/10.1101/2025.02.04.25321635v1
February 5, 2025 at 11:43 PM
A CDE-based data structure for radiotherapeutic decision-making in breast cancer https://www.medrxiv.org/content/10.1101/2025.02.04.25321635v1
Pluvicto now funded in Ontario! We finally have a PSMA radiotherapeutic being reimbursed. www.cbc.ca/news/canada/...
Ontario funding new treatment for advanced-stage prostate cancer | CBC News
Ontario's health minister says the province will now publicly fund a new treatment for advanced-stage prostate cancer.
www.cbc.ca
January 15, 2025 at 4:14 PM
Pluvicto now funded in Ontario! We finally have a PSMA radiotherapeutic being reimbursed. www.cbc.ca/news/canada/...
#NVS Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
https://www.stocktitan.net/news/NVS/ratio-enters-license-and-collaboration-agreement-with-novartis-for-hncggfblfuzf.html
https://www.stocktitan.net/news/NVS/ratio-enters-license-and-collaboration-agreement-with-novartis-for-hncggfblfuzf.html
November 18, 2024 at 1:00 PM
#NVS Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
https://www.stocktitan.net/news/NVS/ratio-enters-license-and-collaboration-agreement-with-novartis-for-hncggfblfuzf.html
https://www.stocktitan.net/news/NVS/ratio-enters-license-and-collaboration-agreement-with-novartis-for-hncggfblfuzf.html